Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting

Roberta Depenni, Maria Cossu Rocca, Daris Ferrari, Giuseppe Azzarello, Cinzia Baldessari, Massimiliano Alù, Franco Nolé, Carla Codecà, Giorgia Boscolo, Marco Piccininni, Stefano Cavalieri, Paolo Bossi

Research output: Contribution to journalArticle

Abstract

Aim: The aims of the study are to evaluate the clinical outcomes of first-line treatment with platinum-based chemotherapy and cetuximab in patients with relapsing/metastatic head and neck cancer (RM HNC) and to identify predictors of treatment response. Methods: This is a retrospective, observational, longitudinal, real-world study involving 6 oncology centres in Italy. All consecutive patients with RM HNC treated between January 2007 and December 2016 with a first-line therapy consisting of a platinum-based chemotherapy regimen plus cetuximab were included. The primary objective of the study was to assess overall survival (OS) and progression-free survival (PFS). Secondary objectives included the identification of predictors of treatment response. Results: Overall, 297 patients were identified. Median OS was 10.8 months (95% confidence interval [CI] 9.3–12.2), whereas median PFS was 4.8 months (95% CI 4.3–5.5). On multivariable analysis, independent unfavourable prognostic factors for OS were performance status (PS) Eastern Cooperative Oncology Group (ECOG) >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Unfavourable predictors for PFS included cancer primary site (paranasal sinuses, hypopharynx), PS ECOG >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Independent unfavourable predictors of objective response were tumour site (oral cavity, larynx-hypopharynx), residual tumour at primary site and prior chemotherapy. Conclusions: The availability of new treatment modalities and epidemiological changes make the periodic reassessment of prognostic factors of great relevance to guide clinical practice and the design of future randomised clinical trials.

Original languageEnglish
Pages (from-to)4-12
Number of pages9
JournalEuropean Journal of Cancer
Volume115
DOIs
Publication statusPublished - Jul 2019

Fingerprint

Head and Neck Neoplasms
Platinum
Residual Neoplasm
Drug Therapy
Disease-Free Survival
Hypopharynx
Survival
Confidence Intervals
Therapeutics
Paranasal Sinuses
Larynx
Italy
Mouth
Neoplasms
Randomized Controlled Trials
Cetuximab

Keywords

  • Cetuximab
  • Head and neck cancer
  • Platinum-based chemotherapy
  • Prognostic factors
  • Relapsing/metastatic disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. / Depenni, Roberta; Cossu Rocca, Maria; Ferrari, Daris; Azzarello, Giuseppe; Baldessari, Cinzia; Alù, Massimiliano; Nolé, Franco; Codecà, Carla; Boscolo, Giorgia; Piccininni, Marco; Cavalieri, Stefano; Bossi, Paolo.

In: European Journal of Cancer, Vol. 115, 07.2019, p. 4-12.

Research output: Contribution to journalArticle

Depenni, Roberta ; Cossu Rocca, Maria ; Ferrari, Daris ; Azzarello, Giuseppe ; Baldessari, Cinzia ; Alù, Massimiliano ; Nolé, Franco ; Codecà, Carla ; Boscolo, Giorgia ; Piccininni, Marco ; Cavalieri, Stefano ; Bossi, Paolo. / Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. In: European Journal of Cancer. 2019 ; Vol. 115. pp. 4-12.
@article{eccab46c389e43ccb4cbf9bc7d255474,
title = "Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting",
abstract = "Aim: The aims of the study are to evaluate the clinical outcomes of first-line treatment with platinum-based chemotherapy and cetuximab in patients with relapsing/metastatic head and neck cancer (RM HNC) and to identify predictors of treatment response. Methods: This is a retrospective, observational, longitudinal, real-world study involving 6 oncology centres in Italy. All consecutive patients with RM HNC treated between January 2007 and December 2016 with a first-line therapy consisting of a platinum-based chemotherapy regimen plus cetuximab were included. The primary objective of the study was to assess overall survival (OS) and progression-free survival (PFS). Secondary objectives included the identification of predictors of treatment response. Results: Overall, 297 patients were identified. Median OS was 10.8 months (95{\%} confidence interval [CI] 9.3–12.2), whereas median PFS was 4.8 months (95{\%} CI 4.3–5.5). On multivariable analysis, independent unfavourable prognostic factors for OS were performance status (PS) Eastern Cooperative Oncology Group (ECOG) >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Unfavourable predictors for PFS included cancer primary site (paranasal sinuses, hypopharynx), PS ECOG >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Independent unfavourable predictors of objective response were tumour site (oral cavity, larynx-hypopharynx), residual tumour at primary site and prior chemotherapy. Conclusions: The availability of new treatment modalities and epidemiological changes make the periodic reassessment of prognostic factors of great relevance to guide clinical practice and the design of future randomised clinical trials.",
keywords = "Cetuximab, Head and neck cancer, Platinum-based chemotherapy, Prognostic factors, Relapsing/metastatic disease",
author = "Roberta Depenni and {Cossu Rocca}, Maria and Daris Ferrari and Giuseppe Azzarello and Cinzia Baldessari and Massimiliano Al{\`u} and Franco Nol{\'e} and Carla Codec{\`a} and Giorgia Boscolo and Marco Piccininni and Stefano Cavalieri and Paolo Bossi",
year = "2019",
month = "7",
doi = "10.1016/j.ejca.2019.03.022",
language = "English",
volume = "115",
pages = "4--12",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting

AU - Depenni, Roberta

AU - Cossu Rocca, Maria

AU - Ferrari, Daris

AU - Azzarello, Giuseppe

AU - Baldessari, Cinzia

AU - Alù, Massimiliano

AU - Nolé, Franco

AU - Codecà, Carla

AU - Boscolo, Giorgia

AU - Piccininni, Marco

AU - Cavalieri, Stefano

AU - Bossi, Paolo

PY - 2019/7

Y1 - 2019/7

N2 - Aim: The aims of the study are to evaluate the clinical outcomes of first-line treatment with platinum-based chemotherapy and cetuximab in patients with relapsing/metastatic head and neck cancer (RM HNC) and to identify predictors of treatment response. Methods: This is a retrospective, observational, longitudinal, real-world study involving 6 oncology centres in Italy. All consecutive patients with RM HNC treated between January 2007 and December 2016 with a first-line therapy consisting of a platinum-based chemotherapy regimen plus cetuximab were included. The primary objective of the study was to assess overall survival (OS) and progression-free survival (PFS). Secondary objectives included the identification of predictors of treatment response. Results: Overall, 297 patients were identified. Median OS was 10.8 months (95% confidence interval [CI] 9.3–12.2), whereas median PFS was 4.8 months (95% CI 4.3–5.5). On multivariable analysis, independent unfavourable prognostic factors for OS were performance status (PS) Eastern Cooperative Oncology Group (ECOG) >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Unfavourable predictors for PFS included cancer primary site (paranasal sinuses, hypopharynx), PS ECOG >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Independent unfavourable predictors of objective response were tumour site (oral cavity, larynx-hypopharynx), residual tumour at primary site and prior chemotherapy. Conclusions: The availability of new treatment modalities and epidemiological changes make the periodic reassessment of prognostic factors of great relevance to guide clinical practice and the design of future randomised clinical trials.

AB - Aim: The aims of the study are to evaluate the clinical outcomes of first-line treatment with platinum-based chemotherapy and cetuximab in patients with relapsing/metastatic head and neck cancer (RM HNC) and to identify predictors of treatment response. Methods: This is a retrospective, observational, longitudinal, real-world study involving 6 oncology centres in Italy. All consecutive patients with RM HNC treated between January 2007 and December 2016 with a first-line therapy consisting of a platinum-based chemotherapy regimen plus cetuximab were included. The primary objective of the study was to assess overall survival (OS) and progression-free survival (PFS). Secondary objectives included the identification of predictors of treatment response. Results: Overall, 297 patients were identified. Median OS was 10.8 months (95% confidence interval [CI] 9.3–12.2), whereas median PFS was 4.8 months (95% CI 4.3–5.5). On multivariable analysis, independent unfavourable prognostic factors for OS were performance status (PS) Eastern Cooperative Oncology Group (ECOG) >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Unfavourable predictors for PFS included cancer primary site (paranasal sinuses, hypopharynx), PS ECOG >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Independent unfavourable predictors of objective response were tumour site (oral cavity, larynx-hypopharynx), residual tumour at primary site and prior chemotherapy. Conclusions: The availability of new treatment modalities and epidemiological changes make the periodic reassessment of prognostic factors of great relevance to guide clinical practice and the design of future randomised clinical trials.

KW - Cetuximab

KW - Head and neck cancer

KW - Platinum-based chemotherapy

KW - Prognostic factors

KW - Relapsing/metastatic disease

UR - http://www.scopus.com/inward/record.url?scp=85065393107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065393107&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2019.03.022

DO - 10.1016/j.ejca.2019.03.022

M3 - Article

C2 - 31082692

AN - SCOPUS:85065393107

VL - 115

SP - 4

EP - 12

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -